Table 1.
Cases of tuberculosis (TB) and incidence rate (IR) in patients receiving TNF inhibitors.
| TNF Inhibitors | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug | Disease | Study type | No~ | Pt-yrs | Active TB cases | IR§ | Rate general population* | Reference |
| Adalimumab | RA, AS, PsA, PsO, CD, UC | LTE | NA | 12,757.7 | 30 | 184.79 | International | Souto et al.27 |
| Certolizumab | RA | LTE | NA | 9277.0 | 44 | 474.29 | International | Souto et al.27 |
| Etanercept | RA, AS, PsA, PsO | LTE | NA | 7164.8 | 3 | 65.01 | International | Souto et al.27 |
| Golimumab | RA, AS, PsA | LTE | NA | 3209.1 | 4 | 172.13 | International | Souto et al.27 |
| Infliximab | RA, AS, PsA, PsO, CD, UC | LTE | NA | 4396.2 | 13 | 347.70 | International | Souto et al.27 |
| Adalimumab | RA, AS, PsA, PsO, CD, UC | RLS | NA | NA | 28 | 215.0 | 8.9 (France) | Tubach et al.28 |
| Adalimumab | RA | RLS | 1190 | NA | 1 | 90.0 | 8.0 (UK) | Dixon et al.9 |
| Adalimumab | RA | RLS | NA | 28,751 | 24 | 83.3 | 8.0 (UK) | Rutherford et al.31 |
| Certolizumab | RA | RLS | NA | 2247 | 2 | 88.8 | 8.0 (UK) | Rutherford et al.31 |
| Etanercept | RA | RLS | 2327 | NA | 0 | NA | 3.0 (USA) | Wolfe et al.8 |
| Etanercept | RA | RLS | 3596 | NA | 2 | 50.0 | 8.0 (UK) | Dixon et al.9 |
| Etanercept | RA | RLS | NA | 36.663 | 17 | 46.3 | 8.0 (UK) | Rutherford et al.31 |
| Etanercept | RA | RLS | NA | NA | 4 | 80.0 | 5.5 (Sweden) | Askling et al.2 |
| Etanercept | RA | RLS | 103 | 73.67 | 0 | NA | 66.0 (Korea) | Seong et al.6 |
| Etanercept | RA, AS, PsA | RLS | NA | NA | 0 | NA | 9.4 (Spain) | Gomez-Reino et al.10 |
| Infliximab | RA, AS, PsA, PsO, CD, UC | RLS | NA | NA | 35 | 187.5 | 8.9 (France) | Tubach et al.28 |
| Infliximab | RA | RLS | 6460 | NA | 4 | 52.5 | 3.0 (USA) | Wolfe et al.8 |
| Infliximab | RA | RLS | 2878 | NA | 7 | 150.0 | 8.0 (UK) | Dixon et al.9 |
| Infliximab | RA | RLS | NA | 17,670 | 13 | 73.4 | 8.0 (UK) | Rutherford et al.31 |
| Infliximab | RA | RLS | NA | NA | 9 | 145.0 | 5.5 (Sweden) | Askling et al.2 |
| Infliximab | RA | RLS | 90 | 78.17 | 2 | 2558.0 | 66.0 (Korea) | Seong et al.6 |
| Infliximab | RA, AS, PsA | RLS | NA | NA | 17 | 1113.0 | 9.4 (Spain) | Gomez-Reino et al.10 |
~
Number of patients included in the study.
§
per 100,000 patient-years.
*
IR for TB infection in general population of certain country per 100,000 population.
AS, ankylosing spondylitis; CD, Crohn’s disease; LTE, long-term extension; NA, not applicable; PsA, psoriatic arthritis; PsO, psoriasis; Pt-yrs, patient-years; RA, rheumatoid arthritis; RLS, real-life study; TNF, tumour necrosis factor; UC, ulcerative colitis.